Canine Patient Recruitment

As of March 30, 2016

If you would like additional information regarding a clinical trial, please contact us at:

Phone: (765) 496-9715
Fax: (765) 496-1108

If you believe your pet is eligible for a specific study, we recommend that you contact your veterinarian and request a referral. However a referral is not required to participate in a clinical trial.

To make an appointment at the Small Animal Hospital please call (765) 494-1107.


Canine Aggression Study in Labrador Retriever, Beagle and Standard Poodle

  • Description: This study is to compare genetic and behavior information between human directed aggressive dogs and non-aggressive (to both humans and animals) dogs in 3 different breeds to see if potential genetic and/or biomarkers may be identified.
  • Eligibility: Pure bred Labrador Retrievers, Beagles or Standard Poodles that are either affected dogs (human aggressive dogs) or control dogs (no aggression toward humans or animals) are eligible.
  • Financial Incentive: no cost for collection of samples (blood). Blood collection can be also performed at the primary veterinarian office and ship to us (cost for blood collection and shipping will be covered).
  • Primary Investigator: Dr. Niwako Ogata

Separation Anxiety disorder and Non-Separation anxiety disorder dogs

  • Description: A study to develop biomarkers to assess anxiety disorders in dogs.
  • Eligibility: Clinically healthy dogs that must be neutered/spayed and between the age of 1.5-7 years old. All participants (either separation anxiety dogs or non-anxious dogs) will be pre-screened for Eligibility through a questionnaire and a 30-minute video clip at home.
  • Financial Incentive: no cost for collection of samples (blood).
  • Primary Investigator: Dr. Niwako Ogata

Dogs with anxiety and/or fear related disorders

  • Description: The purpose of this pilot study is to assess the efficacy of D-Cycloserine (DCS) in dogs with anxiety and/or fear related behavior disorders that are admitted to the Purdue Animal Behavior Service.
  • Eligibility: Evaluation by the behavior service confirms the Eligibility of the study. Pre-bloodwork (CBC and chemistry profile) within 3 months must have already been performed or will be performed before the study by pet owners’ expense.
  • Financial Incentive: Post-bloodwork (CBC and chemistry profile) 1 month after the last dose of DCS will be covered by the study. Three oral doses of DCS will be provided at no charge.
  • Primary Investigator: Dr. Niwako Ogata


Dogs with chronic gastrointestinal disease

  • Description: A collaboration study with Texas A&M to investigate and ultimately control chronic gastrointestinal diseases in dogs.
  • Eligibility: Any dog with chronic small intestinal enteropathies are eligible to enroll
  • Financial Incentive: The following diagnostics are covered by the study: GI panel (TLI, folate, cobalamin), histopathology, and all shipping costs.
  • Primary Investigator: Dr. Nolie Parnell


MRI for dogs suspected to have brain tumors

  • Description: A study to develop MRI in the diagnosis of dogs with brain tumors.
  • Eligibility: Any dog that is suspected to be suffering from a brain tumor. Examination by the Neurology & Neurosurgery service must confirm the suspicion of a brain tumor and Eligibility for the study. Bloodwork and chest radiographs (from within the last month) must have already been performed – these may be performed at the referring veterinarian office before the appointment at Purdue.
  • Financial Incentives: the cost of the MRI is significantly reduced.
  • Primary Investigator: Dr. Timothy Bentley

Surgery and Metronomic Chemotherapy for Brain Tumors in Dogs

  • Description: Combination surgery and chemotherapy for brain tumors in dogs, including a post-operative MRI and a repeat MRI at 3 months. Samples to test the chemotherapy concentrations will be taken during the study.
  • Eligibility: Dogs that have been tentatively diagnosed with a brain tumor by MRI. Chest radiographs and bloodwork must also have been performed (within the last month). Other tests to assess general health may be required before dogs are eligible for enrollment.
  • Financial Incentives: The brain tumor surgery, the chemotherapy, the bloodwork to monitor the chemotherapy and the two repeat MRIs will all be provided at no charge. (Dogs with inoperable brain tumors will be eligible for chemotherapy, bloodwork to monitor the chemotherapy and repeat MRI at 3 months, all provided at no charge).
  • Primary Investigators: Dr. Timothy Bentley


Dogs with Transitional Cell Carcinoma

  • Description: This pilot study is to determine the antitumor effects and the toxicity (or lack thereof) of a folate-targeted therapy.
  • Eligibility: Biopsy diagnosis of naturally-occurring transitional cell carcinoma
    • Confirmed folate receptor expression in the tumor
    • Measurable cancer lesions
    • Expected survival ≥ 6 weeks
  • Financial Incentive: Folate-tubulysin will be provided by a drug company. Most of the expenses related to administering and monitoring the treatment will be paid by the study funding agency. Pet owners will be ask to pay a portion for expenses not covered by the trial.
  • Primary Investigator: Dr. Debbie Knapp

Healthy/Normal Dogs AND dogs suspected or confirmed ofhaving TCC that are admitted to the Purdue Veterinary Teaching Hospital

  • Description: This study is to learn more about the transitional call carcinoma of the urinary bladder in order to develop effective strategies to prevent TCC or to treat it more effectively. We wish to compare the results from dogs who are normal or who have other non-cancer problems in their urinary tract.
  • Eligibility: Healthy dogs or dogs with suspected or confirmed TCC that are at least one year of age that are admitted to the Purdue Veterinary Teaching Hospital
  • Financial Incentive: no cost for collection of samples
  • Primary Investigator: Dr. Debbie Knapp

Dogs with Lymphoma

  • Description: The purpose of this study is to investigate whether an innovative tissue imaging technology, known as biodynamic imaging (BDI) can be used to predict the responsiveness of canine diffuse large B-cell lymphoma (DLBCL) to chemotherapy. 
  • Eligibility: Biopsy- confirmed DLBCL diagnosis of lymphoma
    • No prior chemotherapy or radiation therapy, including prednisone
    • Expected survival of at least 4 weeks
    • Absence of other serious illness
    • Adequate bone marrow function, in order to receive chemotherapy
  • Financial Incentive: Cost of biopsies and initial staging tests are paid for by the study.  Owners' financial responsibility for chemotherapy treatments is capped at $50 per visit to Purdue.  Pet owners are financially responsible for costs arising at from medical management of treatment, as well as other medical conditions not related to Lymphoma.
  • Primary Investigator: Dr. Michael Childress

For more information on Oncology Clinical Investigations please visit their website at:


Dogs With Dry Eye Disease

  • Description: A study to evaluate the injection of stem cells derived from the dog's own fat into the diseased lacrimal glands to return functional tearing.
  • Eligibility: Dogs with documented dry eye that have responded poorly to standard treatment of topical cyclosporine or tacrolimus. Some dogs with extremely chronic lack of any tear production may not qualify for the study.
  • Financial Incentives: Reduced cost of laboratory preparation of stem cells.
  • Primary Investigator: Dr. Jean Stiles

Golden Retriever Pigmentary Uveitis (PU)

  • Description: A study to better understand the disease progression of PU and establish a DNA bank of samples from both affected and normal Golden Retrievers.
  • Eligibility: Any purebred Golden Retriever
  • Financial Incentives: There is no compensation for participation in this study. However the ocular examination is performed at no cost to you.
  • Primary Investigator: Dr. Wendy Townsend


Polyarthritis – folate-receptor targeted drug delivery

  • Description: A study to evaluate a new folate-receptor drug complex for the treatment of immune mediated polyarthritis in dogs. The drug has strong anti-inflammatory activity, similar to the new rheumatoid arthritis drugs for humans.
  • Eligibility: Dogs with naturally occurring immune mediated polyarthritis.
  • Financial Incentives: All costs related to the diagnosis and rechecks through the 16 week recheck will be reimbursed to the owner. The owner is responsible for the cost of the initial visit for diagnosis. During this visit, the scintigraphy will be done free of charge. Once the diagnosis of immune mediated polyarthritis is made, the owner will be advised about Eligibility for enrollment.
  • Primary Investigator: Dr. Gert Breur

    Purdue University College of Veterinary Medicine, 625 Harrison Street, West Lafayette, IN 47907, (765) 494-7607

    @ 2016 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by PVM Web Communications

    If you have trouble accessing this page because of a disability, please contact PVM Web Communications at